Mochida Pharmaceutical Past Earnings Performance
Past criteria checks 1/6
Mochida Pharmaceutical's earnings have been declining at an average annual rate of -3.2%, while the Pharmaceuticals industry saw earnings growing at 4.3% annually. Revenues have been growing at an average rate of 0.08% per year. Mochida Pharmaceutical's return on equity is 3.5%, and it has net margins of 4.3%.
Key information
-3.2%
Earnings growth rate
-1.6%
EPS growth rate
| Pharmaceuticals Industry Growth | 3.4% |
| Revenue growth rate | 0.08% |
| Return on equity | 3.5% |
| Net Margin | 4.3% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Mochida Pharmaceutical (TSE:4534) Will Pay A Dividend Of ¥40.00
Sep 06
Mochida Pharmaceutical (TSE:4534) Is Paying Out A Dividend Of ¥40.00
Aug 22Mochida Pharmaceutical (TSE:4534) Will Pay A Dividend Of ¥40.00
Aug 08Mochida Pharmaceutical (TSE:4534) Is Paying Out A Dividend Of ¥40.00
Jul 25Mochida Pharmaceutical (TSE:4534) Will Pay A Dividend Of ¥40.00
Jul 11Mochida Pharmaceutical's (TSE:4534) Dividend Will Be ¥40.00
Mar 22Mochida Pharmaceutical (TSE:4534) Will Pay A Dividend Of ¥40.00
Mar 02Revenue & Expenses Breakdown
How Mochida Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 104,505 | 4,534 | 33,642 | 12,554 |
| 30 Jun 24 | 103,545 | 4,413 | 33,790 | 12,554 |
| 31 Mar 24 | 102,885 | 4,547 | 33,713 | 12,554 |
| 31 Dec 23 | 100,085 | 3,012 | 34,059 | 13,283 |
| 30 Sep 23 | 99,537 | 5,564 | 31,738 | 13,283 |
| 30 Jun 23 | 100,316 | 5,182 | 33,021 | 13,283 |
| 31 Mar 23 | 103,261 | 6,649 | 33,324 | 13,283 |
| 31 Dec 22 | 106,759 | 8,470 | 32,899 | 12,295 |
| 30 Sep 22 | 109,370 | 9,576 | 33,218 | 12,295 |
| 30 Jun 22 | 110,509 | 11,071 | 32,086 | 12,295 |
| 31 Mar 22 | 110,179 | 10,569 | 32,866 | 12,295 |
| 31 Dec 21 | 107,928 | 10,360 | 33,967 | 10,849 |
| 30 Sep 21 | 105,381 | 8,092 | 34,834 | 10,849 |
| 30 Jun 21 | 102,978 | 7,873 | 33,907 | 10,849 |
| 31 Mar 21 | 102,995 | 8,587 | 31,939 | 10,849 |
| 31 Dec 20 | 102,583 | 6,627 | 30,517 | 11,884 |
| 30 Sep 20 | 101,910 | 5,417 | 30,740 | 11,884 |
| 30 Jun 20 | 102,690 | 4,660 | 31,418 | 11,884 |
| 31 Mar 20 | 101,799 | 4,598 | 31,228 | 11,884 |
| 31 Dec 19 | 101,102 | 4,964 | 31,366 | 13,003 |
| 30 Sep 19 | 103,919 | 6,091 | 30,284 | 13,003 |
| 30 Jun 19 | 106,331 | 5,897 | 30,665 | 13,003 |
| 31 Mar 19 | 109,643 | 8,435 | 30,581 | 13,003 |
| 31 Dec 18 | 110,669 | 9,602 | 30,602 | 11,912 |
| 30 Sep 18 | 109,409 | 10,037 | 30,770 | 11,912 |
| 30 Jun 18 | 107,550 | 10,548 | 29,849 | 11,912 |
| 31 Mar 18 | 106,761 | 9,023 | 29,992 | 11,912 |
| 31 Dec 17 | 108,042 | 8,001 | 29,266 | 15,226 |
| 30 Sep 17 | 105,511 | 8,886 | 28,707 | 15,226 |
| 30 Jun 17 | 101,852 | 9,569 | 28,489 | 15,226 |
| 31 Mar 17 | 97,349 | 8,526 | 29,710 | 15,226 |
| 31 Dec 16 | 93,140 | 9,547 | 29,764 | 13,454 |
| 30 Sep 16 | 93,337 | 8,897 | 30,183 | 13,454 |
| 30 Jun 16 | 94,138 | 8,226 | 30,817 | 13,454 |
| 31 Mar 16 | 92,272 | 8,150 | 29,391 | 13,454 |
| 31 Dec 15 | 92,138 | 9,449 | 28,921 | 11,777 |
| 30 Sep 15 | 90,200 | 9,262 | 28,018 | 11,777 |
| 30 Jun 15 | 89,467 | 8,823 | 29,131 | 11,777 |
| 31 Mar 15 | 87,252 | 7,544 | 29,881 | 11,777 |
| 31 Dec 14 | 89,529 | 7,881 | 31,561 | 11,961 |
| 30 Sep 14 | 91,037 | 8,585 | 32,209 | 11,961 |
| 30 Jun 14 | 92,015 | 9,872 | 31,139 | 11,961 |
| 31 Mar 14 | 93,947 | 9,892 | 31,026 | 11,961 |
| 31 Dec 13 | 92,291 | 10,171 | 29,503 | 12,519 |
Quality Earnings: 4534 has high quality earnings.
Growing Profit Margin: 4534's current net profit margins (4.3%) are lower than last year (5.6%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 4534's earnings have declined by 3.2% per year over the past 5 years.
Accelerating Growth: 4534's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 4534 had negative earnings growth (-18.5%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (12.2%).
Return on Equity
High ROE: 4534's Return on Equity (3.5%) is considered low.